2026 Pharmabiotics Conference

Loading Events

« All Events

2026 Pharmabiotics Conference

February 3, 2026 @ 08:00 - February 5, 2026 @ 17:00

 

The Pharmabiotic Research Institute is delighted to invite you to join us for the 2026 edition of the Pharmabiotics Conference, the Microbiome Conference of Development & Regulation (D&R), taking place in Brussels on February 3–5, 2026.Now in its 10th edition, Pharmabiotics is one of Europe’s oldest and most established microbiome meetings. Over more than a decade, it has earned trust by centering development and regulation, and by turning real regulatory journeys into practical case studies that move the field forward.Four D’s, one R:

Development: Translating microbiome science into real-world products.

Direction: Offering Regulatory compass points in a space that still lacks official guidelines.

Dialogue: A unique platform where researchers, developers, regulators, and industry share their journeys. The conference fosters peer-to-peer exchange while also opening direct dialogue with those writing, interpreting, and implementing the rules that will define the next chapter of microbiome innovation.

Disruption: Showcasing how microbiome science is reshaping health, food systems, and sustainability.

Behind the conference stands the Pharmabiotic Research Institute (PRI), Europe’s Microbiome Regulatory Science Center. PRI is an independent non profit, recognized as a stakeholder with key EU institutions, and supported by the largest microbiome network in Europe. 

For more details…

Details

Start:
February 3, 2026 @ 08:00
End:
February 5, 2026 @ 17:00
Event Category:
Website:
www.pharmabioticsevent.com

Venue

Brussels
Belgium + Google Map
COST

COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. Our Actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation. (www.cost.eu)

COST Action CA23110

Scientific literature is shedding light on the centrality of GI for human health and wellbeing. Indeed, the physiologic effects of nutrients, bioactives and even toxic compounds (including foodborne pathogens) are mediated by their absorption rate in the intestine and by their interaction with gut microbiota and its host ecosystem. Testing food, feed, supplements or drugs in clinical studies gives rise to ethical issues, and the transferability of animal data across species is often problematic because of differences in physiology, metabolism and chemical susceptibilities.

MoU
062/22

CSO Approval Date
27/05/2022

Start Date
06/10/2022

End Date
05/10/2026

2025 | Cost Action CA23110 | All Right Reserved  | Design by Onno Media